Table 3. Univariate and multivariate analyses of factors associated with PFS and OS of all patients.
|
PFS |
OS |
|||||
|---|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
|||
| Parameters | P-value | HR (95% CI) | P-value | P-value | HR (95% CI) | P-value |
| Age ⩾65 years | 0.710 | 0.118 | ||||
| Gender, male | 0.211 | 0.072 | ||||
| ECOG PS score (>2) | 0.029 | 0.053 | ||||
| ISS stage | 0.025 | 0.022 | ||||
| LDH >ULN | 0.013 | 0.002 | ||||
| FISHa | <0.001 | 2.610 (1.670–4.082) | <0.001 | <0.001 | 4.145 (1.836–9.358) | 0.001 |
| Treatment regimensb | 0.003 | 1.784 (1.147–2.775) | 0.010 | 0.060 | ||
| IL-10 level (>164.50 pg ml−1) | <0.001 | 5.885 (3.552–9.750) | <0.001 | <0.001 | 4.708 (2.084–10.637) | <0.001 |
Abbreviations: CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group Performance Status; FISH=interphase fluorescence in situ hybridization; HR=hazard ratio; IL-10=interleukin-10; ISS=International Staging System; LDH=lactate dehydrogenase; OS= overall survival; PFS= progression-free survival; ULN=upper limit of normal.
a
Patients with abnormalities of 13q14, 1q21, 14q32, and 17p13 compared with no FISH abnormalities.
b
Doxil, vincristine, and dexamethasone (DVD) regimen compared with bortezomib-based regimen.